Koolen-de Vries Syndrome was first identified in 2006 and thus is a relatively ``new`` syndrome. Current published literature describing the syndrome is based on small numbers of individuals. Research into the syndrome is still on-going and there is great need for parents/caregivers to get involved. Read more about how you can get involved with GenIDA.
Koolen-de Vries Syndrome is genetic syndrome involving the 17th chromosome and is caused by a microdeletion at 17q21.31 (including the KANSL1 gene) or is caused by a change or mutation of the KANSL1 gene. The microdeletion or the KANSL1 mutation causes developmental delays, learning difficulties and can cause a number of other health concerns.
In 2008, the prevalence of Koolen-de Vries Syndrome was estimated at 1 in 16,000 individuals. The prevalence of the microdeletion is now estimated at 1 in 55,000 individuals. Due to the limited number of identified KANSL1 mutations, at this time the prevalence of the KANSL1 mutation can not be determined. Mutations of KANSL1 may be as frequent as the microdeletion, but more studies are required to determine the prevalence. (Koolen et al. 2016. The Koolen-de Vries syndrome: a phenotypic comparison of patients with a 17q21.31 microdeletion versus a KANSL1 sequence variant. Eur J Hum Genet 24(5): 652-659.)
Koolen-de Vries Syndrome is an autosomal dominant condition, which means a deletion or mutation of one copy of the KANSL1 gene is enough to cause the disorder. Koolen-de Vries Syndrome is not typically inherited, but occurs randomly during the formation of reproductive cells, or during fetal development.
Most patients with Koolen-de Vries Syndrome are the first in their family to be diagnosed with the disorder. In most cases, the parents of children with Koolen-de Vries Syndrome don’t have the disorder. This means that neither parent has the microdeletion or the missing KANSL1 gene. The mutation or deletion happened randomly during fetal development. The likelihood that they will have another child with Koolen-de Vries Syndrome is very low. If patients with Koolen-de Vries Syndrome have children, there is a 50% chance their child will have the disorder.
For patients with Koolen-de Vries Syndrome, there are several recommended therapies that most individuals will find beneficial.. The earliest treatment is physiotherapy for feeding problems and motor delay, followed by physical therapy aimed at strengthening the muscles and core strength. As the child grows, the therapy focuses more on developing the child’s fine and gross motor skills with occupational therapy and continued physical therapy. Speech therapy help improve communication skills by using a multitude of techniques which can include sign language, pictures and Alternative and Augmentative Communication (AAC) or speech devices.
Patients should also seek orthopedic, cardiac, renal, and urologic care from physicians if those symptoms manifest. Neurologists can prescribe medication to help reduce epileptic seizures. Educational materials should also be made available for patients families on how to help care for a patient with Koolen-de Vries.
Researchers continue to collect and analyze medical data and in the future they will develop specific disease management and surveillance strategies. To effectively do this, please submit your child's medical history to GenIDA.
Human Disease Genes is a “library of websites for professional information about genes and copy number variants and their clinical consequences”.
The website includes a page dedicated to Koolen-de Vries Syndrome and the KdVS section is maintained and written by Dr. Koolen and Dr. Eichler. The website provides current information on Koolen-de Vries Syndrome including clinical data, molecular data, disease management, and research.
The information in the Unique guide is drawn from information on the 17q21 website; from articles in the medical literature; and from Unique’s database [Varela 2006; El-Chehadeh-Djebbar 2011; Write 2011; Terrone 2012; Unique]. With the first-named author and publication date you can look for abstracts or original articles on the internet in PubMed.
When this updated guide was compiled, Unique had 51 members with Koolen-de Vries syndrome.
This information is used on the Koolen-de Vries Syndrome Foundation Website with permission from Unique.
Koolen-De Vries syndrome is a rare genetic condition caused by partial loss of part of chromosome 17 [17q21.31 microdeletion], including the gene called KANSL1. It can also be caused by a change in the KANSL1 gene. These
genetic changes can cause developmental delay, learning difficulties, and
create possible health concerns. However, individuals vary, both in the degree to which they are affected and in other effects.
The KANSL1 gene is found on the long arm of chromosome 17. Chromosomes are the structures in the nucleus of the body’s cells that carry genetic information, telling the body how to develop and function. They come in pairs, one from each parent, and are numbered 1 to 22 approximately from largest to smallest. The 23rd pair is the sex chromosomes. XX for females and XY for males. Each chromosome has a short (p) arm and a long (q) arm. KANSL1 is found at a place on the long arm of chromosome 17 called 17q21.31. Until 2012, Koolen-de Vries syndrome was called 17q21.31 Microdeletion Syndrome.
You can’t see chromosomes with the naked eye, but if you stain them and magnify them under a microscope, you can see that each one has a distinctive pattern of light and dark bands. Each band contains millions of
base pairs of DNA. Base pairs are the chemicals in DNA that form the ends of the “rungs” of its ladder-like structure and make up genes.
A technique known as microarray comparative genomic hybridization (array CGH) can show the loss of tiny amounts of DNA from a chromosome or a change in a particular gene. Using this technique, laboratory geneticists can see whether the 17q21.31 region including the KANSL1 gene is missing. Another technique known as FISH can also be used to show that DNA is missing, but these techniques do not show tiny changes in the KANSL1 gene. A technique known as DNA sequence analysis is used to identify small changes in KANSL1 at the base pair level.
The KANSL1 gene is found between base pair 44,107,282-44,302,733 on chromosome 17. These numbers are from Human Genome build 19. The human genome is updated as more information is found; each new version is called a “build”. In each build, the base pair numbers may change slightly. In February 2013, hg19 is the newest build. Confusingly, hg19 is also sometimes called Genome Reference Consortium human genome 37, GRCh37. In the previous build hg18, KANSL1 was found between base pairs 41,463,129-41,658,510.